BioCentury
ARTICLE | Clinical News

Telavancin: Phase II FAST2 data

December 13, 2004 8:00 AM UTC

In the double-blind, international Phase II FAST 2 trial in 201 patients, those treated with once daily telavancin had clinical cure rates of 96.1% compared to 93.5% treated with standard therapy of t...